Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.52 |
| ▸ | SLC5A2 | P31639 | 10/20 | 0.42 |
| ▸ | UMPS | P11172 | 1/20 | 0.40 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiazofurin SCHEMBL4453888 | 0.87 | PYGL (0.53) | PYGLUMPS | |
| Tiazofurin SCHEMBL4287 | 0.87 | PYGL (0.53) | PYGLUMPS | |
| SCHEMBL7832887 | 0.87 | PYGL (0.53) | PYGLSLC5A2UMPSGALR3NR2F2 | |
| Tiazofurin SCHEMBL23264566 | 0.87 | PYGL (0.53) | PYGLUMPS | |
| Tiazofurin SCHEMBL2883659 | 0.87 | PYGL (0.53) | PYGLUMPS | |
| Tiazofurin SCHEMBL23848843 | 0.87 | PYGL (0.53) | PYGLUMPS | |
| Tiazofurin SCHEMBL13109276 | 0.87 | PYGL (0.53) | PYGLUMPS | |
| Tiazofurin SCHEMBL1651851 | 0.87 | PYGL (0.53) | PYGLUMPS | |
| Tiazofurin SCHEMBL2883657 | 0.87 | PYGL (0.53) | PYGLUMPS | |
| Tiazofurin SCHEMBL7169632 | 0.87 | PYGL (0.53) | PYGLUMPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110033422-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | SCHERING CORPORATION | 2011-02-10 | — | — | US | disclosed |
| US-7524831-B2 | Treatments for Flaviviridae virus infection | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033422-A1 | TREATMENTS FOR FLAVIVIRIDAE VIRUS INFECTION | HAVCR2, EIF2AK2, HNRNPC | PYGL 1084/4885SLC5A2 4145/4885UMPS 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.